Merck and Pfizer’s immunotherapy fails in late-stage trial

15th February 2018 Uncategorised 0

Bavencio (avelumab) has failed to meet its primary endpoint in a lung cancer trial

More: Merck and Pfizer’s immunotherapy fails in late-stage trial
Source: News